<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191007045023N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-06-29</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Epidural Analgesia and Dural Puncture Analgesia (Spinal/CSE) in Painless Natural Childbirth for Hospitalized Pregnant Women</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of Epidural Analgesia and Dural Puncture Analgesia (Spinal/CSE) in Painless Natural Childbirth for Hospitalized Pregnant Women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>126</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/82384</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Other, Randomization description: A table of random numbers will be used to randomize the study participants. To achieve this, the researcher will first determine the direction of movement in the table of random numbers and then place their finger on one of the cells. They will then proceed to move in the predetermined direction. The even numbers identified will be assigned to the conventional epidural group, and the odd numbers will be assigned to the DPE (dural puncture epidural) group. This process will continue until the required sample size is completed, Blinding description: The present study will be conducted as a double-blind trial. To maintain blinding, outcome assessors will remain unaware of the intervention type through the use of randomized codes (e.g., A and B), generated by an independent system and kept confidential until the final analysis. Any identifiers linked to group assignments will be omitted during data collection. Furthermore, by ensuring identical interventions in both groups (in terms of appearance, administration method, and duration) and prohibiting information disclosure by the research team, patients will also remain blinded to their group allocation.".</study_design>
      <phase>3</phase>
      <hc_freetext>Analgesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After identifying the epidural space in the DPE group, a 27-gauge Whitacre pencil-point needle will be inserted using the needle-through-needle technique, perforating the meninges. The needle stylet is then removed to observe the free flow of cerebrospinal fluid (CSF). Once confirmed, the spinal needle is withdrawn, and after injecting 3 mL of normal saline, the epidural catheter will be inserted. The catheter will be fixed in place similarly to the other group. If the aspiration test for blood or CSF is positive, the catheter will be reinserted, and the patient will be excluded from the study. After confirming negative aspiration, a loading dose of 5 micrograms of sufentanil and 10 mL of 0.1% ropivacaine will be administered slowly over 5 minutes with repeated aspirations. An infusion of 10 mL per hour of 0.1% ropivacaine with sufentanil (0.1 micrograms per mL) will then be initiated. In cases where the patient's VAS pain score exceeds 5, 5 mL of 0.1% ropivacaine with 5 micrograms of sufentanil will be administered as emergency analgesia 30 minutes after the initial bolus dose. The time of epidural initiation will be recorded, along with the time required to achieve a VAS score half of the baseline, the VAS score after ten minutes, and the time taken for the VAS score to drop below 3. Intervention 2: Control group: In the group receiving conventional epidural anesthesia, 3 mL of normal saline is injected through the epidural needle, and an 18-gauge epidural catheter is placed into the epidural space, directed cephalad. After this step, the epidural needle is removed, and the epidural catheter is secured so that 3 centimeters remain within the epidural space.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Patient data is collected for research purposes only and cannot be published.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Amineh Shafei nia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Molavi street, Molavi intersection, Ferdowsi garden station</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>116874351411</zip>
        <telephone>+98 21 5560 6034</telephone>
        <email>shafeinia.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Amineh Shafei nia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Molavi street, Molavi intersection, Ferdowsi garden station</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>116874351411</zip>
        <telephone>+98 21 5560 6034</telephone>
        <email>shafeinia.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 and under 40 years
Full-term pregnancy (gestational age between 37-42 weeks)
American Society of Anesthesiologists (ASA) class I and II
Body mass index between 20 and 25 kg/m²
ervical dilation between 2 and 5 centimeters</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Unwillingness to participate in the study
Cases complicated by brain or cardiovascular dysfunction
Patients who received opioid injections prior to the induction of anesthesia;
Patients with spinal column disorders;
Preterm delivery
Patients with adverse pregnancy outcomes
Contraindications for epidural block
Patients who deliver within less than one hour from the placement of the epidural catheter</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P04.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Newborn (suspected to be) affected by maternal anesthesia and analgesia in pregnancy, labor and delivery</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After identifying the epidural space in the DPE group, a 27-gauge Whitacre pencil-point needle will be inserted using the needle-through-needle technique, perforating the meninges. The needle stylet is then removed to observe the free flow of cerebrospinal fluid (CSF). Once confirmed, the spinal needle is withdrawn, and after injecting 3 mL of normal saline, the epidural catheter will be inserted. The catheter will be fixed in place similarly to the other group. If the aspiration test for blood or CSF is positive, the catheter will be reinserted, and the patient will be excluded from the study. After confirming negative aspiration, a loading dose of 5 micrograms of sufentanil and 10 mL of 0.1% ropivacaine will be administered slowly over 5 minutes with repeated aspirations. An infusion of 10 mL per hour of 0.1% ropivacaine with sufentanil (0.1 micrograms per mL) will then be initiated. In cases where the patient's VAS pain score exceeds 5, 5 mL of 0.1% ropivacaine with 5 micrograms of sufentanil will be administered as emergency analgesia 30 minutes after the initial bolus dose. The time of epidural initiation will be recorded, along with the time required to achieve a VAS score half of the baseline, the VAS score after ten minutes, and the time taken for the VAS score to drop below 3.</i_keyword>
      <i_keyword>Control group: In the group receiving conventional epidural anesthesia, 3 mL of normal saline is injected through the epidural needle, and an 18-gauge epidural catheter is placed into the epidural space, directed cephalad. After this step, the epidural needle is removed, and the epidural catheter is secured so that 3 centimeters remain within the epidural space.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Achieving the desired anesthesia. Timepoint: 10 minutes after the interventions. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Maternal satisfaction with analgesia. Timepoint: after intervention. Method of measurement: Checklist.</sec_outcome>
      <sec_outcome>Newborn Apgar score. Timepoint: 1 and 5 minutes after birth. Method of measurement: Checklist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-07-21</approval_date>
        <contact_name>Iran university of medical sciences</contact_name>
        <contact_address>Next to Milad Tower, Hemat Highway ,Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
